Julian Gangolli is a proven and respected senior executive with a visible and successful track record at highly regarded publicly traded companies. He joined Allergan in 1998 and was North American President when it was sold in 2015, after becoming one of the leading specialty pharmaceutical companies in the United States.
Mr. Gangolli joined GW Pharmaceuticals in 2015 as US President. As President he oversaw the approval of the first CBD drug by the FDA and the subsequent successful commercialization of Epidiolex® in the US. Epidiolex® is indicated for the treatment of refractory epilepsies and seizures in children. The commercial success of Epidiolex® in the US led to the acquisition of GW Pharmaceuticals by Jazz Pharmaceuticals in 2021 for over $7 billion.